ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia Thumbnail Image Read more about ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia
BioInvent Announces Positive Efficacy Data in CTCL Cohort of Patients with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program Thumbnail Image Read more about BioInvent Announces Positive Efficacy Data in CTCL Cohort of Patients with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program
Caribou Biosciences Announces the FDA has Granted Fast Track Designation to CB-012 in Relapsed or Refractory AML Thumbnail Image Read more about Caribou Biosciences Announces the FDA has Granted Fast Track Designation to CB-012 in Relapsed or Refractory AML
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML Thumbnail Image Read more about Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
ImCheck Awarded EUR 20.18 Million from the French Government Through the France 2030 Investment and Innovation Plan Thumbnail Image Read more about ImCheck Awarded EUR 20.18 Million from the French Government Through the France 2030 Investment and Innovation Plan
Faron Announces Positive FDA Feedback Regarding Registration Study Plan in MDS Thumbnail Image Read more about Faron Announces Positive FDA Feedback Regarding Registration Study Plan in MDS
Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer Thumbnail Image Read more about Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer
FDA Grants Fast Track Designation for Bexmarilimab in r/r MDS Thumbnail Image Read more about FDA Grants Fast Track Designation for Bexmarilimab in r/r MDS
Research Accelerator for Follicular Lymphoma I (RAFL-I) Thumbnail Image Read more about Research Accelerator for Follicular Lymphoma I (RAFL-I)
X4 Pharmaceuticals Announces FDA Approval of Mavorixafor, First Drug Indicated in Patients with WHIM Syndrome Thumbnail Image Read more about X4 Pharmaceuticals Announces FDA Approval of Mavorixafor, First Drug Indicated in Patients with WHIM Syndrome
